How GLP-1 Medications Work: A Clinical Overview
GLP-1 receptor agonists are currently the most effective pharmacological treatments for obesity and overweight available in the UK. Understanding how they work at a clinical level helps patients make informed decisions about treatment, set realistic expectations for how their body will respond, and understand why certain side effects occur and how to manage them. This guide provides a plain-English but clinically accurate explanation of the GLP-1 system, how the medications activate it, and what this means in practice.
What GLP-1 Is and Where It Comes From
Glucagon-like peptide-1 (GLP-1) is a naturally occurring incretin hormone produced by L-cells in the small intestine and colon in response to food consumption. In physiological conditions, GLP-1 is released within minutes of eating and serves several coordinated functions: it stimulates the pancreas to release insulin in a glucose-dependent manner (meaning it only triggers insulin release when blood glucose is elevated, which is why GLP-1 medications carry a low risk of hypoglycaemia in non-diabetic patients); it suppresses glucagon release, reducing hepatic glucose output; it slows gastric emptying, prolonging the period over which nutrients are absorbed from the small intestine; and it activates satiety signalling pathways in the hypothalamus, reducing hunger and food intake.
In the natural state, GLP-1 is degraded by the enzyme dipeptidyl peptidase-4 (DPP-4) within one to two minutes of release, giving it a very short half-life. The pharmaceutical GLP-1 receptor agonists used in weight management are structural analogues of native GLP-1 that have been engineered to resist DPP-4 degradation, enabling sustained receptor activation from a once-weekly injection.
The Hypothalamic Appetite Pathway: Where Weight Loss Actually Starts
The most clinically significant mechanism of GLP-1 receptor agonists for weight loss is their direct action on GLP-1 receptors in the hypothalamus, particularly in the arcuate nucleus, which is the brain’s primary appetite regulation centre. Activation of GLP-1 receptors in the arcuate nucleus reduces the firing of orexigenic (hunger-promoting) NPY/AgRP neurons and increases the activity of anorexigenic (satiety-promoting) POMC neurons. The net effect is a sustained reduction in perceived hunger, a reduced drive to eat, and an earlier onset of satiety during meals.
This central mechanism is critically different from the peripheral mechanisms of older weight loss approaches. The patient does not feel they are fighting hunger through willpower; the hypothalamic regulation of appetite is genuinely altered by the medication. Patients typically describe noticing that food is less compelling, portion sizes feel more satisfying, and the persistent background hunger that characterises attempts to reduce caloric intake through diet alone is largely absent.
Gastric Emptying: The Role of Slowed Digestion
GLP-1 receptor activation in the gastrointestinal tract slows gastric emptying, the rate at which food moves from the stomach into the small intestine. This produces two clinically important effects. First, it prolongs the physical sensation of stomach fullness after a meal, reinforcing the central satiety signal. Second, it slows the rate of glucose absorption from the gut, which contributes to improved post-meal blood glucose control and is one of the reasons GLP-1 medications are also effective treatments for type 2 diabetes.
The slowing of gastric emptying is also the principal driver of the gastrointestinal side effects associated with these medications, particularly nausea. When gastric motility is significantly slowed, the stomach becomes more sensitive to volume and can trigger nausea responses. This is why the slow dose titration schedule prescribed with both semaglutide and tirzepatide is clinically important: it allows physiological tolerance to develop gradually.
Semaglutide and Tirzepatide: The Two Available Options in the UK
Two GLP-1 receptor agonists are currently licensed for weight management in the UK. Semaglutide (Wegovy) is a GLP-1 receptor agonist given as a once-weekly subcutaneous injection, licensed by the MHRA for weight management in adults with a BMI of 30 kg/m2 or above, or 27 kg/m2 or above with at least one weight-related comorbidity. Tirzepatide (Mounjaro) is a dual GIP and GLP-1 receptor agonist, also given as a once-weekly subcutaneous injection and licensed for the same indications. The dual mechanism of tirzepatide, which activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor simultaneously, is associated with greater average weight loss in clinical trials than semaglutide alone
Clinical Evidence: The STEP 1 trial of semaglutide 2.4 mg demonstrated a mean weight loss of 14.9 percent of body weight at 68 weeks in adults with obesity, compared to 2.4 percent with placebo. The SURMOUNT-1 trial of tirzepatide 15 mg demonstrated a mean weight loss of 22.5 percent of body weight at 72 weeks, compared to 2.4 percent with placebo. Both trials enrolled adults without type 2 diabetes, with BMI at or above 30 kg/m2.
What GLP-1 Medications Cannot Do
GLP-1 receptor agonists are clinically effective tools for weight management but they are not metabolic reset buttons. They work most effectively when combined with a modest caloric deficit and increased physical activity. They do not change body composition independently: preservation of lean muscle mass during weight loss requires adequate protein intake and resistance exercise. Patients who continue the medication long-term are more likely to maintain weight loss; discontinuation is associated with weight regain in the majority of patients, as the hypothalamic appetite effect is dependent on continued medication.
Clinical Disclaimer: This guide is for general informational purposes only and does not constitute personalised medical advice. Curelo Care is regulated by the General Pharmaceutical Council (GPhC). All weight management medication supplied by Curelo Care is provided following a structured online clinical assessment and prescriber review. If you have any questions about your treatment, please contact our clinical team.
